ZharfAI Team
AI can propose a protein sequence, rank a metabolic pathway, predict a structure, or recommend a fermentation condition. It cannot grant biosafety approval, establish that an organism is safe to handle or release, prove that a product works, or demonstrate that a manufacturing process will consistently meet specification. Those conclusions require institutional and regulatory authority, controlled experiments, validated analytical methods, and production evidence.
The useful model is therefore not “biology as software.” Biology is a variable, evolving physical system. Computation can make the design-build-test-learn cycle more informative, but every design must return to measurement, containment, review, and traceable manufacturing.
Start with the intended product and use: research reagent, enzyme, industrial chemical, food ingredient, agricultural input, biomaterial, diagnostic, or therapeutic. Name the host organism, production environment, scale, exposure routes, waste streams, target market, and applicable authorities.
Separate evidence classes:
A sequence with a high model score has not advanced automatically through these classes.
Before models propose or rank biological designs, conduct a documented risk assessment covering the organism, genetic material, procedure, quantity, equipment, personnel competence, exposure, environment, and consequences of accidental or deliberate misuse. NIH policy for research involving recombinant or synthetic nucleic-acid molecules explains institutional biosafety committee responsibilities for covered organizations. Assign the committee, biosafety officer, principal investigator, security owner, and escalation route.
Use risk-based controls: facility and engineering containment, access, training, inventory, transport, decontamination, waste, incident response, occupational health, and emergency plans. Review cyberbiosecurity, sequence and model access, remote laboratory tools, and sensitive design information.
The WHO’s 2024 laboratory biosecurity guidance explicitly includes molecular techniques and AI in a consequence-driven lifecycle. It complements, rather than replaces, local law and institutional review.
Create a design brief with function, permitted host, operating conditions, forbidden capabilities, sequence constraints, off-target concerns, manufacturability, assay plan, and stop criteria. Restrict models to approved datasets and design spaces. Record dataset source, license, organism, assay, laboratory, version, and quality.
Apply appropriate screening and expert review to proposed sequences and orders under applicable policy. Do not let a generative system bypass order screening, institutional approval, material-transfer terms, export controls, or access restrictions.
Preserve every proposal, model version, parameter, prompt or objective, score, reviewer action, and disposition. A rejected design should remain auditable without being broadly exposed.
AI should produce testable hypotheses, not only attractive candidates. Predefine controls, replicates, randomization, blinding where feasible, assay validity, success thresholds, and statistical analysis. Include negative and reference designs. Test whether performance arises from the intended mechanism rather than contamination, measurement artifact, selection bias, or a proxy.
Use orthogonal assays for identity, activity, purity, stability, and unintended products. Characterize the host and product across relevant conditions. A protein-structure prediction does not establish expression, folding, function, toxicity, immunogenicity, or stability in the intended system.
Connect discovery work to bioinformatics and clinical trials only through the appropriate preclinical, manufacturing, and human-research gates.
Assign persistent identifiers to source data, design, construct, host, cell bank, material lot, protocol, assay, instrument, culture, harvest, purification run, sample, batch, and result. Record who performed each action, when, under which approved protocol and equipment state.
Maintain genotype and phenotype evidence, passage or generation history, storage conditions, chain of custody, deviations, and changes. Link a reported result to raw data and the exact biological material tested.
Digital lineage does not replace physical controls. Labels, barcodes, inventory reconciliation, segregation, environmental monitoring, and independent sample identity testing remain necessary.
Scale changes oxygen transfer, mixing, shear, heat removal, gradients, contamination risk, morphology, expression, growth, by-products, and yield. Build a process model around critical quality attributes and critical process parameters rather than assuming a flask result will reproduce in a bioreactor.
Develop upstream and downstream operations together: inoculum, media, feeding, induction, harvest, clarification, purification, formulation, fill, storage, and waste. Establish sampling and analytical methods for identity, purity, potency or activity, contaminants, residuals, stability, and other product-specific attributes.
Use AI to analyze multivariate process data or propose experiments, but require engineering review and change control before a recommendation becomes a setpoint.
FDA’s process-validation guidance describes a lifecycle that includes process design, qualification, and continued verification for regulated drug and biological-product manufacturing. A specific product’s requirements depend on its legal category and jurisdiction.
Qualification should show that facilities, utilities, equipment, software, methods, people, and process can operate as intended. Continued verification should monitor drift, variability, deviations, out-of-specification results, maintenance, suppliers, and changes.
For U.S. biological products that require a Biologics License Application, FDA’s BLA process evaluates safety, effectiveness, and manufacturing quality. An AI design paper or successful pilot batch is not marketing authorization.
Release decisions must use approved specifications, validated or qualified methods, complete batch records, deviation assessment, environmental and contamination controls, and authorized quality review. Model predictions may support investigation or prioritization; they should not silently replace required testing.
Define which actions AI may take:
Retain the measurements used for each release and the versioned rules in effect at that time.
Split datasets by laboratory, batch, strain family, campaign, and time so near-duplicate experiments do not leak into test sets. Measure performance on unseen constructs, hosts, equipment, media lots, and scales. Report uncertainty and abstention.
For design models, evaluate enrichment over a realistic baseline, hit rate after experimental confirmation, diversity, novelty, feasibility, and failure mechanisms. For process models, measure prediction error by operating regime, early-warning horizon, false alarms, calibration, and effect of interventions.
Track whether recommendations improve validated yield or quality after accounting for additional experiments, analyst time, failed runs, and compute. Simulation success is not production yield.
Useful KPIs include:
Candidate count, predicted score, or liters fermented are not substitutes for safe, conforming product.
Plan for concrete failure modes:
For each, define detection, containment, responsible authority, quarantine, investigation, notification, correction, and evidence needed to resume.
Begin with a low-consequence, non-production research task inside an approved design space. Establish dataset lineage, model evaluation, sequence screening, biosafety review, and assay controls. Keep proposals advisory and measure experimental enrichment against a baseline.
Next, introduce AI into pilot process development in shadow mode. Validate sensors, methods, data capture, scale assumptions, and operator review. Use controlled change management and preapproved experimental ranges.
Only after quality and safety thresholds are met should recommendations enter production workflows. Preserve independent quality authority, manual fallback, model rollback, validated exports, supplier exit, incident drills, and periodic re-review.
For food-related applications, connect production evidence to food safety and traceability. Sustainability claims must include feedstocks, energy, water, purification, waste, and full process yield, not only the organism’s theoretical pathway.
Source status was checked on 2026-07-30. NIH’s March 2026 grants-policy section on research involving recombinant or synthetic nucleic acid molecules explains applicability of the NIH Guidelines and institutional biosafety committee responsibilities for covered organizations. The WHO Laboratory Biosafety Manual, fourth edition uses an evidence- and risk-based approach, while WHO’s 2024 Laboratory Biosecurity Guidance adds consequence-driven controls across material, technology, information, and emerging technologies including AI. FDA’s final Process Validation guidance describes lifecycle principles for drug and biological-product manufacturing. FDA’s BLA process resource distinguishes investigational evidence from the comprehensive safety, effectiveness, and manufacturing-quality package used for U.S. licensure. These sources do not approve a particular AI design or biomanufacturing product.
How event-driven chips and brain-inspired architectures could reduce AI energy use—and where benchmarks, software maturity, and manufacturing still limit adoption.
Read More
AI can analyze spectra and prioritize experiments in quantum biology, but functional claims require physics-constrained tests that rule out classical explanations.
Read More
A robot is a physical safety system, not a clever model; autonomy should stay bounded, update-resistant, measurable, and paired with meaningful human authority.
Read MoreIf this note maps to a real system in your organization, start with the services page or a shipped case study.